Form 4: Pediatrix Executive Reports Stock Transactions

Don Gregory Neeb, EVP Chief Invest & Strategy at Pediatrix Medical Group, Inc., reported transactions involving restricted stock and tax withholdings.

Summary

• Don Gregory Neeb, EVP, Chief Invest & Strategy for Pediatrix Medical Group, Inc. (MD), reported a grant of 63,888 restricted shares on June 1, 2026, with no cost associated.
• Additionally, 8,003 restricted shares were withheld on June 1, 2026, for tax payments, at a price of $21.54 per share.
• Following these transactions, Neeb beneficially owns 137,231 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine equity awards and tax withholdings by an executive, rather than significant strategic shifts or performance indicators.

Positives

• Grant of 63,888 restricted shares indicates continued equity-based compensation and potential alignment with company performance.
• The reporting person continues to hold a significant number of shares (137,231) after the reported transactions.

Negatives

• Withholding of 8,003 restricted shares for tax payments represents a reduction in the total number of shares held by the reporting person.

Risks

• The vesting schedule for the restricted shares (25% on June 1, 2027, 25% on June 1, 2028, and 50% on June 1, 2029) means the reporting person's full benefit from the award is contingent on continued employment and vesting conditions.
• The tax withholding transaction implies a tax liability, which is a normal part of equity compensation but reduces the net shares received.

Future Outlook

The restricted shares granted have a phased vesting schedule, with portions vesting on June 1, 2027, June 1, 2028, and June 1, 2029, subject to the terms of the Issuer's Second Amended and Restated 2008 Incentive Compensation Plan.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The grant of restricted stock is a common method for executive compensation in the healthcare services industry, aiming to retain talent and align executive interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The transaction reflects standard executive compensation practices, with no immediate direct impact on share price, but the vesting schedule aligns executive incentives with long-term company performance.
• Employees: The filing pertains to an executive's compensation, not directly impacting general employee compensation or benefits.
• Management: The reporting person, Don Gregory Neeb, continues to be compensated through equity awards, indicating ongoing engagement and incentive alignment.

Next Steps

• Vesting of restricted shares on June 1, 2027, June 1, 2028, and June 1, 2029, contingent upon plan terms.
• Potential future sales of vested shares by the reporting person, subject to applicable regulations and trading plans.

Key Dates

Keywords

Form 4, SEC Filing, Pediatrix Medical Group, MD, Insider Trading, Stock Transaction, Restricted Stock, Equity Award, Tax Withholding, Beneficial Ownership, Don Gregory Neeb